Clinical Trial

The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 3, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Long-term glucocorticoids therapy is associated with various complications, including decreased bone strength (Glucocorticoid-induced osteoporosis) and an increased risk of fracture. Vitamin K2 has been recently deemed appreciable as a topic of research as it plays a pivotal role in maintenance of the bone strength, and it has been proved to have a positive impact on the bone metabolism. This study examines the impact of oral vitamin K2 supplementation on bone metabolism in pediatric patients with nephrotic syndrome on long-term steroid therapy, offering valuable therapeutic insights
Trial Details
NCT Number NCT07206537
Lead Sponsor Ain Shams University
Conditions Pediatrics Nephrology
Enrollment 60 participants
Start Date 2025-04-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-03